LifeWatch claims that BCBS and associated groups “shielded themselves from patient demand for the seller’s device by agreeing to deny coverage as ‘not medically necessary’ or ‘investigational,’ even while the medical community, other insurers, and independent arbiters viewed it as befitting the standard of care,” according to court documents.
Judges for the Third Circuit court of appeals, after examining the case, ruled that LifeWatch had “plausibly pled an agreement between the Blue Plans and the Association that unreasonable restrains trade in the national market for outpatient cardiac monitors,” and reversed a previous dismissal of the case.
Third Circuit Judges commented that while they reversed the dismissal, they believed that Blue Cross “may be exempt from liability under the McCarran-Ferguson Act,” and remanded it so that BCBS’s associated argument could be considered, according to court documents.
In March 2016, LifeWatch said that an arbitrator from the International Centre for Dispute Resolution ruled against the firm and in favor of Highmark Blue Cross Blue Shield to the tune of $18.7 million.
Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.
At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!
Use code WOMENSHEALTH to save an additional 10%.